Brain metastasis as exclusion criteria in clinical trials involving extensive-stage small cell lung cancer.

Non-US and single systemic therapy studies are more commonly associated with strict exclusion of brain metastasis in ES-SCLC trials. The strict exclusion of brain metastases in clinical trials has remained relatively constant for the past few decades.